A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy.
1/5 보강
A comprehensive pathological evaluation is useful for diagnosing synchronous multiple primary lung cancer (sMPLC).
APA
Fukui D, Morinaga D, et al. (2026). A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy.. Respiratory investigation, 64(2), 101375. https://doi.org/10.1016/j.resinv.2026.101375
MLA
Fukui D, et al.. "A case of synchronous multiple primary lung cancers each harboring an EGFR mutation or an ALK fusion gene alone that responded to osimertinib with chemotherapy.." Respiratory investigation, vol. 64, no. 2, 2026, pp. 101375.
PMID
41564844
Abstract
A comprehensive pathological evaluation is useful for diagnosing synchronous multiple primary lung cancer (sMPLC). However, a consensus regarding treatment for sMPLC with different driver mutations is lacking. We present a case of sMPLC harboring an epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) fusion gene. For the advanced EGFR-positive tumor, osimertinib plus chemotherapy was initiated, the latter also covering ALK-positive tumor. A marked response and slight reduction occurred in the EGFR-positive and ALK-positive tumors, respectively. Surgical resection of the ALK-positive tumor achieved negative margins. Targeted therapy with chemotherapy may effectively treat sMPLC with different driver mutations.
MeSH Terms
Humans; Lung Neoplasms; Acrylamides; Aniline Compounds; Anaplastic Lymphoma Kinase; ErbB Receptors; Mutation; Neoplasms, Multiple Primary; Antineoplastic Combined Chemotherapy Protocols; Oncogene Proteins, Fusion; Male; Middle Aged; Female; Indoles; Pyrimidines